Skip to content
SARMWADA ProhibitedCompare

LGD-4033

Also known as: Ligandrol, LGD4033, Anabolicum

6
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

LGD-4033 is one of the most studied SARMs, with the Basaria et al. (2013) placebo-controlled trial showing a clean dose-dependent 1.2 kg lean-mass gain at just 1 mg/day over 21 days alongside dose-dependent testosterone/SHBG/HDL suppression. Real-world users typically run 5-10mg/day (5-10x the highest studied clinical dose), so both the muscle-building effect and the suppression seen in practice are almost certainly larger than what the trial captured. It is banned by WADA, confirming its performance-enhancing status. Gains are real but more modest than injectable anabolic steroids, so it sits alongside RAD-140 in the mid-enhanced SARM tier, below testosterone (7).

Overview

A non-steroidal SARM highly effective for mass accrual. One of the most studied SARMs with clinical trial data supporting its muscle-building effects.

Important Warnings

  • Not approved for human use
  • Banned by WADA and most sports organizations
  • Clinically suppressive (Basaria trial): dose-dependent drops in testosterone, FSH, HDL and SHBG; run PCT and monitor lipids
  • SARM hair loss is androgen-receptor-mediated. Finasteride/dutasteride will NOT prevent it
  • Multiple published case reports of drug-induced liver injury from bodybuilding LGD-4033 products, including one patient (10mg/day for ~2 weeks, within the typical community dose range) who developed severe cholestatic hepatitis with jaundice and bilirubin up to 35 mg/dL

Purpose & Use Cases

Mass Building

One of the best SARMs for adding significant muscle mass.

Strength Gains

Produces noticeable strength increases throughout the cycle.

Recovery Enhancement

Improves recovery between training sessions.

Benefits

  • Significant muscle mass gains
  • Increased strength
  • Enhanced recovery
  • No estrogen conversion
  • Oral administration
  • Clinical trial data available

Good to Know

One of the few SARMs with real human trial data

The Basaria placebo-controlled trial (76 healthy men, up to 1 mg/day for 21 days) showed clean dose-dependent lean-mass gains (~1.2 kg at 1 mg in 3 weeks) alongside dose-dependent suppression of testosterone, SHBG, HDL and triglycerides (free testosterone and FSH reached significance at the 1 mg dose). Hormones and lipids returned to baseline after stopping. This is why LGD is considered effective but genuinely suppressive, and real-world users typically dose 5-20x higher than anything tested in that trial.

Suppression is dose-dependent. Dose it accordingly and run PCT

At low doses (5 mg) many recover with a mini-PCT (low-dose enclomiphene); at higher doses or longer runs, treat it like a full androgen cycle with a proper SERM PCT. "It is only a SARM" is exactly the mindset that leaves people with lingering low testosterone.

Hair loss is AR-mediated. Finasteride will not help

LGD-4033 does not convert to DHT, so people assume it is hair-safe. It still activates the androgen receptor at the scalp directly, which can accelerate loss in predisposed men. Because there is no DHT-conversion step, finasteride/dutasteride do nothing here.

Muscle memory and the raised natural ceiling

Myonuclei added while training on LGD persist after the cycle, making future re-gains easier, but a chunk of on-cycle scale weight is water/glycogen, and keeping real muscle depends on recovering endogenous testosterone via PCT. The lasting benefit is a modestly raised re-gain ceiling, not permanent retention of peak-cycle size.

Dosage Guidelines

Experience LevelDosage Range
Beginner55 mg/day
Intermediate510 mg/day
Advanced1020 mg/day
Frequency
Once daily oral
Typical Cycle Length
812 weeks
Notes

The Basaria clinical trial only tested up to 1 mg/day; real-world/black-market users typically run 5-10mg/day and some push to 15-20mg, 5-20x the studied clinical range, with unknown extra risk. Higher doses show diminishing returns and increased suppression/lipid strain (community-derived, not clinical data).

Side Effects

Testosterone Suppression

very common
Severity
3/5

Dose-dependent suppression of natural testosterone.

Mitigation

Mini-PCT or full PCT depending on cycle length and dose.

HDL Decrease

common
Severity
2/5

Reduction in good cholesterol levels.

Mitigation

Omega-3 fatty acids; regular cardio.

Water Retention

uncommon
Severity
1/5

Mild water retention in some users.

Mitigation

Usually resolves post-cycle.

General Mitigation Strategies

Mini-PCT for shorter/lower dose cycles. Full PCT for longer cycles. Monitor lipids with bloodwork.

Support Supplements

Ancillary supplements commonly run alongside LGD-4033 to manage side effects, support the target tissue, or fill nutrient demands it creates.

Lipid support (omega-3 + citrus bergamot)

Key

LGD-4033 dose-dependently lowers HDL and triglycerides in clinical data. Omega-3 supports triglycerides; citrus bergamot helps LDL.

Dose
Omega-3 2-4 g/day; citrus bergamot 500-1,000 mg/day
Timing
With meals
When
The higher the dose, the more the lipid hit: a lipid panel before and during is worthwhile.

Post Cycle Therapy (PCT)

⚠️PCT Required

Mini-PCT with Enclomiphene (6.25-12.5mg daily) for 4 weeks, or Nolvadex if heavily suppressed.

How It Works

LGD-4033 binds to androgen receptors with high selectivity for muscle and bone. It increases protein synthesis and nitrogen retention, leading to significant muscle growth without the typical androgenic side effects of steroids.

Hormonal & Androgenic Profile

Aromatizes (→ estrogen)none
Natural test suppressionsevere
Hair loss risk (DHT-prone)moderate
Liver toxicitylow
DHT-derivativeNo
Progestogenic (19-nor)No
Anabolic : Androgenic ratio

Highly muscle-selective in preclinical assays (leading AR binding affinity, Ki 0.9 nM); androgenic activity on skin/scalp is low but not zero in practice.

Estrogen control

Does not aromatize, no AI needed for LGD-4033 itself. Any estrogen management is only relevant if an aromatizing base (e.g. testosterone) is stacked.

DHT / 5-AR & finasteride

Not a 5-alpha-reductase substrate, so finasteride/dutasteride do not help with LGD-related shedding. Any hair loss is from direct androgen-receptor activation at the follicle, which finasteride cannot address.

Cardiovascular impact

Clinically shown to dose-dependently suppress HDL and triglycerides; no estrogenic water retention. Suppression and lipids reversed after discontinuation in the trial.

Fundamentals

WADA Status

Prohibited by WADA
Category: S1. Anabolic Agents
In-Competition: ProhibitedOut-of-Competition: Prohibited

LGD-4033 (Ligandrol) is explicitly listed as a prohibited SARM under S1.2 Other Anabolic Agents.

References

Last updated: July 18, 2026